130 related articles for article (PubMed ID: 18489666)
1. The burden of ankylosing spondylitis in Spain.
Kobelt G; Sobocki P; Mulero J; Gratacos J; Pocovi A; Collantes-Estevez E
Value Health; 2008; 11(3):408-15. PubMed ID: 18489666
[TBL] [Abstract][Full Text] [Related]
2. Costs and quality of life of patients with ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660
[TBL] [Abstract][Full Text] [Related]
3. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
4. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong.
Zhu TY; Tam LS; Lee VW; Hwang WW; Li TK; Lee KK; Li EK
Rheumatology (Oxford); 2008 Sep; 47(9):1422-5. PubMed ID: 18635597
[TBL] [Abstract][Full Text] [Related]
5. Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
[TBL] [Abstract][Full Text] [Related]
6. [RAISE study observational and cross sectional study to evaluate the actual reality of the socio-economic impact of ankylosing spondylitis].
Miranda L; Negreiro F; Queiroz MJ; Silva C
Acta Reumatol Port; 2008; 33(2):189-97. PubMed ID: 18604185
[TBL] [Abstract][Full Text] [Related]
7. Assessment of work disability in seronegative spondyloarthritis.
Rohekar S; Pope J
Clin Exp Rheumatol; 2010; 28(1):35-40. PubMed ID: 20346236
[TBL] [Abstract][Full Text] [Related]
8. [The reliability and validity of a Croatian version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with ankylosing spondylitis].
Grazio S; Grubisić F; Nemcić T; Matijević V; Skala H
Reumatizam; 2009; 56(2):63-76. PubMed ID: 20429263
[TBL] [Abstract][Full Text] [Related]
9. Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey.
Akkoç N; Direskeneli H; Erdem H; Gül A; Kabasakal Y; Kiraz S; Balkan Tezer D; Hacıbedel B; Hamuryudan V
Rheumatol Int; 2015 Sep; 35(9):1473-8. PubMed ID: 25749712
[TBL] [Abstract][Full Text] [Related]
10. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis.
Robertson LP; Davis MJ
Rheumatology (Oxford); 2004 Dec; 43(12):1565-8. PubMed ID: 15353608
[TBL] [Abstract][Full Text] [Related]
11. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
12. Costs and work limitation of patients with ankylosing spondylitis in China.
Tu L; Rai JC; Cao S; Lin Z; Hu Z; Gu J
Clin Exp Rheumatol; 2014; 32(5):661-6. PubMed ID: 25234798
[TBL] [Abstract][Full Text] [Related]
13. Validation of the Tunisian versions of Bath Ankylosing Spondylitis Functional Index (BASFI) and Disease Activity Index (BASDAI).
Kchir MM; Hamdi W; Kochbati S; Azzouz D; Daoud L; Saadellaoui K; Ghannouchi MM; Kaffel D; Ben Hamida A; Zouari B
Tunis Med; 2009 Aug; 87(8):527-30. PubMed ID: 20180357
[TBL] [Abstract][Full Text] [Related]
14. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
15. Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index in Turkish patients with ankylosing spondylitis: relationship with disease activity and quality of life.
Zahiroglu Y; Ulus Y; Akyol Y; Tander B; Durmus D; Bilgici A; Kuru O
Int J Rheum Dis; 2014 Feb; 17(2):173-80. PubMed ID: 24576273
[TBL] [Abstract][Full Text] [Related]
16. Is disease severity in ankylosing spondylitis genetically determined?
Hamersma J; Cardon LR; Bradbury L; Brophy S; van der Horst-Bruinsma I; Calin A; Brown MA
Arthritis Rheum; 2001 Jun; 44(6):1396-400. PubMed ID: 11407700
[TBL] [Abstract][Full Text] [Related]
17. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis.
Taylor AL; Balakrishnan C; Calin A
Arthritis Rheum; 1998 Jun; 41(6):1119-25. PubMed ID: 9627023
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis.
Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
J Rheumatol; 1999 Apr; 26(4):961-5. PubMed ID: 10229428
[TBL] [Abstract][Full Text] [Related]
19. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
20. The Swedish version of the Bath ankylosing spondylitis disease activity index. Reliability and validity.
Waldner A; Cronstedt H; Stenström CH
Scand J Rheumatol Suppl; 1999; 111():10-6. PubMed ID: 10503554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
